Study Design
This is a randomized controlled clinical trial, with two parallel groups, with a
1:1 allocation rate, conducted from January to July 2018. The Consolidated of
Reporting Trials (CONSORT) for Randomized Trials of Nonpharmacologic Treatments
was followed